Investment
Features
FeesSafety
Academy
More
Pluang+

Compare TransMedics Group Inc (TMDX) vs T-Mobile Us Inc (TMUS) Price & Performance

TransMedics Group IncTrade
T-Mobile Us IncTrade

Price performance (Past 24H)

Key statistics

TransMedics Group Inc vs T-Mobile Us Inc — how do they compare? TransMedics Group Inc trades at $77.87 (market cap $2.74B), while T-Mobile Us Inc trades at $148.58 (market cap $183.76B). The key difference: T-Mobile Us Inc is far larger — about 67.1× TransMedics Group Inc's market cap, and T-Mobile Us Inc pays a 2.73% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and T-Mobile Us Inc for 84 Days on average.

TMDXTMUS
Market Cap
$2.74B$183.76B
Volume
949,3314,294,650
Sector
HealthMedia
52-Week High
$150.42$230.06
52-Week Low
$61.99$161.73
Typical Hold Time
24 Days84 Days
Enterprise Value
$3.13B$300.37B
Dividend Yield
—2.73%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

TransMedics Group Inc

TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.

The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.

T-Mobile Us Inc

TMUS trades at $171.31, up 2.2% today, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth to $88.31B in 2025. The company announced a 15% dividend hike and is advancing AI-driven 5G network upgrades, while maintaining robust profitability with a net margin of 11.45%.

Outlook remains positive given earnings momentum and strategic initiatives, but risks include high debt levels and competitive pressures. The consensus price target of $231.10 implies significant upside, supported by 79.6% buy ratings from analysts.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

TMDX
95% Buy5% Sell
Avg holding period · 24 Days
TMUS
53% Buy47% Sell
Avg holding period · 84 Days

Top news

Latest headlines on both assets

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX →

About T-Mobile Us Inc

Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.

Read more on TMUS →